220 related articles for article (PubMed ID: 31445531)
1. [Live Vaccine in Children with DiGeorge/22q11.2 Deletion Syndrome].
Miranda M; Martins AT; Carvalho S; Serra-Caetano A; Esteves I; Marques JG
Acta Med Port; 2019 Aug; 32(7-8):514-519. PubMed ID: 31445531
[TBL] [Abstract][Full Text] [Related]
2. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).
Perez EE; Bokszczanin A; McDonald-McGinn D; Zackai EH; Sullivan KE
Pediatrics; 2003 Oct; 112(4):e325. PubMed ID: 14523220
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of measles-mumps-rubella vaccine in children with congenital immunodeficiency (DiGeorge syndrome).
Azzari C; Gambineri E; Resti M; Moriondo M; Betti L; Saldias LR; G Gelli AM; Vierucci A
Vaccine; 2005 Feb; 23(14):1668-71. PubMed ID: 15705470
[TBL] [Abstract][Full Text] [Related]
4. Live vaccine use and safety in DiGeorge syndrome.
Hofstetter AM; Jakob K; Klein NP; Dekker CL; Edwards KM; Halsey NA; Baxter R; Williams SE; Graham PL; LaRussa P
Pediatrics; 2014 Apr; 133(4):e946-54. PubMed ID: 24685951
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients.
Kawano Y; Suzuki M; Kawada J; Kimura H; Kamei H; Ohnishi Y; Ono Y; Uchida H; Ogura Y; Ito Y
Vaccine; 2015 Mar; 33(12):1440-5. PubMed ID: 25665961
[TBL] [Abstract][Full Text] [Related]
6. Humoral immunity in DiGeorge syndrome.
Junker AK; Driscoll DA
J Pediatr; 1995 Aug; 127(2):231-7. PubMed ID: 7636647
[TBL] [Abstract][Full Text] [Related]
7. Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands.
Tielemans SMAJ; de Melker HE; Hahné SJM; Boef AGC; van der Klis FRM; Sanders EAM; van der Sande MAB; Knol MJ
BMJ; 2017 Aug; 358():j3862. PubMed ID: 28855159
[No Abstract] [Full Text] [Related]
8. Live viral vaccines in a DiGeorge syndrome patient.
Waters V; Peterson KS; LaRussa P
Arch Dis Child; 2007 Jun; 92(6):519-20. PubMed ID: 16798784
[TBL] [Abstract][Full Text] [Related]
9. Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome.
Suksawat Y; Sathienkijkanchai A; Veskitkul J; Jirapongsananuruk O; Visitsunthorn N; Vichyanond P; Pacharn P
J Clin Immunol; 2017 May; 37(4):375-382. PubMed ID: 28429103
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
[TBL] [Abstract][Full Text] [Related]
11. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports.
Croce E; Hatz C; Jonker EF; Visser LG; Jaeger VK; Bühler S
Vaccine; 2017 Mar; 35(9):1216-1226. PubMed ID: 28162821
[TBL] [Abstract][Full Text] [Related]
12. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
13. The Immune Phenotype of Patients with CHARGE Syndrome.
Hsu P; Ma A; Barnes EH; Wilson M; Hoefsloot LH; Rinne T; Munns C; Williams G; Wong M; Mehr S
J Allergy Clin Immunol Pract; 2016; 4(1):96-103.e2. PubMed ID: 26563674
[TBL] [Abstract][Full Text] [Related]
14. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).
Jawad AF; McDonald-Mcginn DM; Zackai E; Sullivan KE
J Pediatr; 2001 Nov; 139(5):715-23. PubMed ID: 11713452
[TBL] [Abstract][Full Text] [Related]
15. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine.
Stratton KR; Howe CJ; Johnston RB
JAMA; 1994 May; 271(20):1602-5. PubMed ID: 8182813
[TBL] [Abstract][Full Text] [Related]
16. Early vaccinations are not risk factors for celiac disease.
Myléus A; Stenlund H; Hernell O; Gothefors L; Hammarström ML; Persson LÅ; Ivarsson A
Pediatrics; 2012 Jul; 130(1):e63-70. PubMed ID: 22732174
[TBL] [Abstract][Full Text] [Related]
17. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.
Klein NP; Weston WM; Kuriyakose S; Kolhe D; Howe B; Friedland LR; Van Der Meeren O
Vaccine; 2012 Jan; 30(3):668-74. PubMed ID: 22064267
[TBL] [Abstract][Full Text] [Related]
18. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections.
Sørup S; Benn CS; Poulsen A; Krause TG; Aaby P; Ravn H
JAMA; 2014 Feb; 311(8):826-35. PubMed ID: 24570246
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Immunological Defects and Outcomes in Patients with Chromosome 22q11.2 Deletion Syndrome.
Yu HH; Chien YH; Lu MY; Hu YC; Lee JH; Wang LC; Lin YT; Yang YH; Chiang BL
J Clin Immunol; 2022 Nov; 42(8):1721-1729. PubMed ID: 35925483
[TBL] [Abstract][Full Text] [Related]
20. Low thymic output, peripheral homeostasis deregulation, and hastened regulatory T cells differentiation in children with 22q11.2 deletion syndrome.
Ferrando-Martínez S; Lorente R; Gurbindo D; De José MI; Leal M; Muñoz-Fernández MA; Correa-Rocha R
J Pediatr; 2014 Apr; 164(4):882-9. PubMed ID: 24461789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
